Background: In December 2007, the USFDA approved recombinant human thyroid
stimulating hormone (rhTSH) for radioiodine remnant ablation after total thyroidectomy in …

Background: Multiple studies have demonstrated successful radioactive iodine remnant
ablation (RRA) following preparation with recombinant human thyroid stimulating hormone …

Introduction. Recombinant human thyroid stimulating hormone (rhTSH) is approved for
preparation of thyroid remnant ablation with radioactive iodine (RAI) in low risk patients with …

Objective To evaluate the efficacy of recombinant human thyroid stimulating hormone
[rhTSH (versus hypothyroidism)] in thyroid ablation with an activity of 1.1 GBq (30 mCi) 131 I …

Background: Most patients with well-differentiated thyroid cancer (WDTC) are first treated by
total thyroidectomy followed by remnant ablation (RA) with 131I. There are less data …

To supplement limited relevant literature, we retrospectively compared ablation and disease
outcomes in high‐risk differentiated thyroid carcinoma (DTC) patients undergoing …

Radioiodine remnant ablation (RRA) is frequently used after a thyroidectomy for
differentiated thyroid carcinoma because it has been reported to reduce the number of local …

Context: After surgery for differentiated thyroid carcinoma, many patients are treated with
radioiodine to ablate remnant thyroid tissue. This procedure has been performed with the …

Background: Radioiodine (131I) remnant ablation (RRA) has become a key step in the
postoperative treatment of differentiated thyroid cancer (DTC). However, inadequate or …

Objective To review and comment on current indica tions for radioiodine remnant ablation
(RRA) in patients with differentiated thyroid cancer. Methods The stratification of patients as …